| Literature DB >> 29215161 |
Folkert Steinhagen1, Thomas Zillinger2, Konrad Peukert1, Mario Fox1, Marcus Thudium1, Winfried Barchet2,3, Christian Putensen1, Dennis Klinman4, Eicke Latz5, Christian Bode1.
Abstract
Type I interferon (IFN) is a critical mediator of autoimmune diseases such as systemic lupus erythematosus (SLE) and Aicardi-Goutières Syndrome (AGS). The recently discovered cyclic-GMP-AMP (cGAMP) synthase (cGAS) induces the production of type I IFN in response to cytosolic DNA and is potentially linked to SLE and AGS. Suppressive oligodeoxynucleotides (ODN) containing repetitive TTAGGG motifs present in mammalian telomeres have proven useful in the treatment of autoimmune diseases including SLE. In this study, we demonstrate that the suppressive ODN A151 effectively inhibits activation of cGAS in response to cytosolic DNA, thereby inhibiting type I IFN production by human monocytes. In addition, A151 abrogated cGAS activation in response to endogenous accumulation of DNA using TREX1-deficient monocytes. We demonstrate that A151 prevents cGAS activation in a manner that is competitive with DNA. This suppressive activity of A151 was dependent on both telomeric sequence and phosphorothioate backbone. To our knowledge this report presents the first cGAS inhibitor capable of blocking self-DNA. Collectively, these findings might lead to the development of new therapeutics against IFN-driven pathologies due to cGAS activation.Entities:
Keywords: Autoimmunity; Cytosolic sensor; Double-stranded DNA; Interferons; TREX1
Mesh:
Substances:
Year: 2017 PMID: 29215161 PMCID: PMC6386451 DOI: 10.1002/eji.201747338
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532